COMMENTARY . . .
“I am from the government and I am here to help” . . . the most frightening words in the English language.
Most of the problems we have are created
by the government under the guise of wanting to help the citizens. Part D was a good idea that has gone bad.
Prior to 2006, seniors did not have a drug plan benefit, and there was no OOP cap on the cost of medications. There was also more help from private organizations offering a PAP (prescription assistance
program). Most of those went away when Part D went into effect.
After 2006, the average retail prices of widely used prescription drugs, especially those for chronic conditions, outpaced the rate of general inflation.
The average retail price of brand-name drugs saw substantial increases, more than doubling in inflation-adjusted dollars since 2009.
New, high-cost brand-name drugs, some of which offered treatment for previously untreatable conditions, contributed to increased
spending. Additionally, some manufacturers were able to create or exploit monopolies for certain drugs, leading to sustained high prices.
Economists know that when the cost of goods is subsidized, by insurance coverage or government (taxpayer) “contributions”, the result is always higher prices.
The Catch-22 is, once the government starts “paying” for something they will never cut back. Rather, the underlying cost of the product will be shifted to the consumer and politicians on both sides of the aisle will blame the other.
Brand name prescription drug prices for 2026 will be higher, including those imported from Canada and other non-U.S. sources. I hope to have more input on this in a future newsletter but for now, my Magic 8 ball says the future is cloudy.